Joseph Shaw profile picture

Contact Information

Joseph Shaw, MD, MSc, FRCPC

ORCID logo

Joseph Shaw

Associate Scientist, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Assistant Professor, Department of Medicine
University of Ottawa

Research Interests

Venous thromboembolic disease (VTE)

Anticoagulant pharmacokinetics/pharmacodynamics

Thrombin generation assays and their applications towards the study of VTE and anticoagulation-associated bleeding complications

Brief Biography

Joseph R. Shaw, MD MSc FRCPC is a hematologist and thrombosis medicine specialist in the Department of Medicine at The Ottawa Hospital. He is an Associate Scientist at the Ottawa Hospital Research Institute and an Assistant Professor in the Faculty of Medicine at the University of Ottawa. He completed his undergraduate studies in Biochemistry at McGill University, followed by his M.D., Internal Medicine and Hematology training at the University of Ottawa, as well as Royal College of Physicians and Surgeons AFC training in Adult Thrombosis Medicine through the Thrombosis Unit at The Ottawa Hospital. He also completed a Master of Science in Epidemiology through the University of Ottawa. His thesis dissertation was on the utility of thrombin generation assays towards measuring the anticoagulant effects of direct oral anticoagulants and anticoagulation reversal. 

Dr. Shaw’s research is focused on evaluating anticoagulation reversal strategies, as well as the perioperative management of anticoagulants. He is interested in studying the potential clinical applications of thrombin generation assays, including evaluating anticoagulant pharmacodynamics and the effects of reversal agents and hemostatic therapies. He is currently the lead investigator for a prospective observational study (GAUGE) evaluating the effects of prothrombin complex concentrates on thrombin generation parameters among patients with direct Xa inhibitor-associated bleeding. Dr. Shaw holds grant funding through the PSI Foundation for the GAUGE study.

He has presented his research at national and international conferences. His research on biomarker-enhanced VTE risk stratification among patients with cancer was awarded the Canadian Hematology Society’s John H. Crookston Award in 2019 and his publication on the perioperative management of anticoagulation among patients with cancer-associated VTE was recognized with the Journal of Thrombosis and Haemostasis’ Editors Award in 2020.

Selected Publications

1. Shaw JR., Castellucci LA., Siegal D., Carrier M. (2023). DOAC-associated bleeding, hemostatic strategies and thrombin generation assays - a review of the literature. J Thromb Haemost. 2022 Dec 22;S1538-7836(22)07643-7. doi: 10.1016/j.jtha.2022.11.029. Online ahead of print

Aziz J., Wang TF., Siegal D., Douketis J., Le Gal G., Carrier M., Shaw JR. (2022). Thrombotic and bleeding outcomes following the perioperative interruption of anticoagulation among patients with nonvalvular atrial fibrillation and active cancer. 2022 Dec 27;S1538-7836(22)18255-3. doi: 10.1016/j.jtha.2022.12.016. Online ahead of print.

3. Shaw JR.
, Li N., Nixon J., Moffat KA., Spyropoulos AC., Schulman S., Douketis JD. (2022). Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure. J Thromb Haemost;
20(12): 2953-2963
4. Shaw JR., Kumar V., Mallick R., Carrier M., Ilich A., Key N., Wells P. (2020) Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. Thromb Res; 196: 437-443

5. Shaw JR., Li N., Vanassche T., Coppens M., Spyropoulos A.C., Syed S., Radwi M., Duncan J., Schulman S., Douketis J. (2020) Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Advances; 4(15): 3520-3527

6. Shaw JR., Kaplovitch E., Douketis J. (2020) Periprocedural management of oral anticoagulation. Med Clin North Am; 104(4): 709-726

7. Shaw JR., Carrier M, Dowlatshahi D, Chakraborty S, Tokessy M, Buyukdere H, Castellucci LA (2020). Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes. Thromb Res;195: 21-28.

8. Shaw JR., Siegal D.M. (2020). Prothrombin complex concentrates for DOAC-associated bleeding, global coagulation assays, and assessments of clinical hemostasis: How to gauge the impact? Res Pract Thromb Haemost; 4(5): 677-679

9. Shaw JR., Douketis J., Le Gal G., Carrier M (2019). Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes. J Thromb Haemost; 17(7): 1171-1178

10. Shaw JR., Siegal D.M. (2018). Pharmacological reversal of the direct oral anticoagulants – A comprehensive review of the literature. Res Pract Thromb Haemost; 2:251-265

Diseases, conditions and populations of interest

Research and clinical approaches